What Coyote Bioscience does

Coyote Bioscience Co., Ltd., founded in 2009 in Beijing, is a privately held molecular diagnostics company specializing in point-of-care testing (POCT) platforms for infectious disease detection. The company has built three generations of fully automated instruments under the FlashDetect™ brand — Mini8 Plus (portable), Flash20/Flash48 (mid-to-high throughput), and Flash10/Robo/Nano (compact high-throughput and near-patient) — all powered by its proprietary Parallel Molecular Reaction technology, protected by 95 domestic and international patents and validated across NMPA Class III, CE-IVDR, Brazil ANVISA, and WHO recognition (Mini8 for Ebola). The instruments run proprietary All-in-One cartridges (LyocartD, LyocartE) with pre-loaded lyophilized reagents that integrate sample preparation, nucleic acid extraction, and qPCR amplification, enabling sample-to-result in 10–30 minutes with limits of detection as low as 100–200 copies/mL for SARS-CoV-2 and related pathogens.

Coyote generates revenue through a razor-and-blade model: upfront hardware sales of FlashDetect instruments to hospitals, CDCs, customs authorities, airports, and event organizers (priced on a quote basis), recurring consumables revenue from proprietary Lyocart cartridges (24/48/96-test kits), and managed-services revenue from its wholly-owned Coyote Clinical Laboratory in Beijing, which is qualified by the city to perform PCR testing and processed more than 10 million COVID-19 tests during the pandemic. The company also sells integrated mobile laboratory (BSL-2 ambulatory) deployments that combine Flash20 instruments and Flash Matrix configurations capable of 135,000 tests per day. International expansion has reached 65+ countries, with named deployments at Stockholm Arlanda Airport, hospitals in Italy and Thailand, and government health programs in Mexico and the UAE, supported by regional distributors, direct enterprise sales, and a US R&D subsidiary in Mountain View, CA. Funding includes Series A (RMB 30M from SAIF Asia, 2013), Series B (RMB 80M, 2015), and an undisclosed Series D, supplemented by a RMB 120 million national research grant under China's 15th Five-Year Plan (2025).

The company's go-to-market combines enterprise field sales for large institutional and government accounts, distributor-led coverage in international markets, and high-visibility event-driven deployments (Beijing 2022 Winter Olympics, Tokyo 2020 Olympics delegation screening, CIFTIS, Global Digital Economy Conference) that function as reference accounts. Manufacturing is split between GMP-certified facilities in Yixing (Jiangsu) and Tianjin, with R&D in Beijing and Silicon Valley. Coyote's strategic positioning rests on rapid decentralized molecular diagnostics with minimal infrastructure footprint — addressing pain points of long conventional PCR turnaround times, biosafety risk, and shortage of trained laboratory personnel in decentralized settings including airports, border crossings, event venues, and community-level hospitals.

Name

Coyote Bioscience

Legal name

Coyote Bioscience Co., Ltd.

Website

https://en.coyotebio.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Coyote Bioscience is a Beijing-based molecular diagnostics company founded in 2009 that develops fully automated point-of-care PCR instruments (FlashDetect™) and proprietary lyophilized cartridges for rapid infectious disease detection, serving hospitals, CDCs, airports, customs authorities, and event organizers across 65+ countries.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Point-of-Care Testing (POCT)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Veterinary Services (541940)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

akta.pro secondary industries

Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Veterinary POCT & Rapid Diagnostics (Animal health rapid tests) (HLAHAOAL), Veterinary Microbiology & Infectious Disease Testing (Culture/PCR/Serology) (HLAMADAC), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD), Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)

Keywords

• Molecular point-of-care testing
• Rapid PCR diagnostics
• Infectious disease detection
• Molecular diagnostic instruments
• Lyophilized reagent cartridges

Headquarters

HQ city

Beijing (Haidian District)

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Molecular Diagnostic Instruments (Hardware): Sale of FlashDetect instrument platforms including Nano, Flash10, Flash20, Flash48, Robo, and Mini8 Plus. Instruments are sold directly and through distributors to hospitals, CDCs, government agencies, and other institutions. Revenue from both initial instrument placement and consumable recurring revenue.
2. Diagnostic Reagents and Assays: Sale of proprietary assay cartridges (LyocartD, LyocartE series) and rapid PCR frozen reagents for infectious disease detection (SARS-CoV-2, influenza, MTB, STIs, HAIs, etc.). Recurring consumables revenue driven by test volume on installed instrument base. All-in-One cartridges include pre-loaded lyophilized reagents.
3. Molecular Testing Services: Coyote operates Coyote Clinical Laboratory Co., Ltd. in Beijing providing third-party molecular diagnostic testing services. Certified by Beijing as qualified nucleic acid PCR testing provider. During pandemic, processed more than 10 million tests across 18 provinces.
4. Mobile Laboratory Deployment: Deployment of FlashDetect Mobile Labs (BSL-2 ambulatory COVID-19 testing laboratories) to hospitals, airports, railway stations, and event venues. Mobile labs equipped with Flash20 RT-PCR systems and Flash Matrix (135,000 tests/day capacity). Revenue from deployment, equipment, and testing services.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Coyote Bioscience develops, manufactures, and sells molecular point-of-care testing (POCT) instruments and proprietary All-in-One lyophilized reagent cartridges under its FlashDetect™ platform. Products enable rapid, fully automated sample-to-result molecular diagnostics (15-30 minutes) for infectious diseases including SARS-CoV-2, influenza, RSV, MTB, STIs, HAIs, Ebola, and monkeypox. The company also operates a third-party clinical laboratory and mobile lab deployment services for outbreak response.

Product overview

Coyote Bioscience offers a comprehensive molecular point-of-care testing (POCT) platform called FlashDetect™, consisting of three generations of instruments (Mini8 Plus, Flash20/Flash48, and Nano/Flash10/Robo) that work with proprietary All-in-One lyophilized reagent cartridges. The product architecture follows a modular approach: the FlashDetect platform is the core technology enabling rapid, automated molecular diagnostics, while specific reagent cartridges (LyocartD, LyocartE series) provide application-specific testing for respiratory infections (SARS-CoV-2, Flu A/B, RSV), sexually transmitted infections (CT/NG/UU, MG/TV/MH, HSV), tuberculosis, MRSA, and monkeypox. The Flash20/Flash48 serve mid-to-high throughput laboratory settings, while Nano and Flash10 target point-of-care and decentralized testing with their compact, fully automated sample-to-answer workflow. The Robo system addresses high-volume screening needs. All platforms leverage Coyote's proprietary 'Molecular In-Parallel Reaction' technology enabling sample-to-answer in 15-30 minutes.

Differentiator

Problem solved

Functional benefit

Products and services

• FlashDetect™ Nano A fully automated, near-patient molecular POCT system that delivers sample-to-answer results in 10-20 minutes using fully enclosed All-in-One cartridges. Features built-in scanner, LCD screen, speaker, and mobile app connectivity for Android and iOS. Compact, backpack-portable design compatible with power banks for field deployment. Targets hospitals, airports, field responders, and decentralized testing settings.
• FlashDetect™ Flash10 A high-throughput rapid PCR system designed to work with fully enclosed All-in-One cartridges. Delivers results in less than 25 minutes with 4 random-access modules, automated sample loading, magnetic bead sample preparation, and qPCR on a contamination-free cartridge. Approved by CE IVDR and China NMPA for IVD use.
• FlashDetect™ Robo A fully automated high-throughput rapid PCR system designed for fully enclosed All-in-One cartridges. Capable of up to 2,300 tests/day with 32 sample input slots, automated sample loading, magnetic beads sample preparation, and qPCR amplification.
• FlashDetect™ Flash20 A rapid RT-PCR detection system with 4 random-accessible modules capable of running different assays simultaneously. Uses patented parallel molecular reaction technology achieving 1-minute sample prep and 30-minute sample-to-result with LoD of 200 copies/mL. Scalable up to 64 samples with FlashDetect Matrix configuration. CE-IVDR certified and widely adopted by hospitals, airports, and Olympic venues.
• FlashDetect™ Flash48 High-throughput rapid PCR system completing 48 samples in 48 minutes with sample-to-answer in approximately 1 hour. Features 4 fluorescence channels and temperature gradient capability for versatile PCR applications. Tailor-made for small/medium labs, mobile labs, and on-site testing.
• FlashDetect™ Mini8 Plus A compact, portable, calibration-free real-time qPCR system weighing only 2.1 kg. Registered as a Class III medical device in China and selected into the WHO official recommended list. Enables on-site molecular detection with 8-sample throughput and universal consumables. Used internationally for Ebola, Zika, and African Swine Fever detection.
• FlashDetect™ Mobile Lab Ambulatory COVID-19 testing laboratory designed as a BSL-2 lab meeting PCR-lab standards. Mobile cabin laboratory with integrated P2 biosafety and vehicle-mounted design, enabling on-site, instant, and mobile testing with 10,000+ daily test capability (Flash Matrix capable of 135,000 tests/day). Deployed to hospitals, airports, railway stations, and event venues.
• Coyote Clinical Laboratory Testing Services Third-party molecular diagnostic testing services operated by Coyote Clinical Laboratory Co., Ltd. in Beijing. Certified by Beijing as a qualified nucleic acid PCR testing provider. Processed more than 10 million COVID-19 tests across 18 provinces during the pandemic; provides molecular testing services to hospitals, government agencies, and public events.
• FlashDetect™ SARS-CoV-2 & Influenza A/B Multiplex Assay Rapid multiplex PCR assay for simultaneous detection and differentiation of SARS-CoV-2 and Influenza A/B viruses. Runs on the Flash20 qPCR instrument with sample-to-result in 30 minutes. For hospital and clinical laboratory use during respiratory virus season.
• FlashDetect™ LyocartE SARS-CoV-2 & Flu A & Flu B & RSV Assay
• FlashDetect™ LyocartE MTB Assay
• FlashDetect™ LyocartD/E SARS-CoV-2 Assay
• FlashDetect™ LyocartE MRSA & SA Assay
• FlashDetect™ LyocartE Monkeypox Virus Assay
• DirectDetect™ SARS-CoV-2 Detection Kit
• FlashDetect™ LyocartD/E CT & NG & UU Assay

Quantifiable outcome

• Sample-to-result in 30 minutes vs. 3-4 hours for conventional PCR — up to 4x faster
• +7 more outcomes

Named customers12 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature10 records

Partnerships

Ten partnerships are on record, tiered core, regional and minor.

• China CDC (Chinese Center for Disease Control and Prevention)coreStrategic or Co-development Partner · 1 January 2025Coyote cooperated with China CDC for systematic bioinformatics analyses and experimental validation of SARS-CoV-2 variants including Delta and Omicron strains. Company declared that detection performance of SARS-CoV-2 kit was not affected by mutations. Ongoing collaboration on emerging infectious disease diagnostics.
• Peking Union Medical College HospitalcoreStrategic or Co-development Partner · 1 January 2023Key research partner in national infectious disease research program under China's 15th Five-Year Plan (RMB 120 million funding). Collaborates on next-generation ultra-fast, highly sensitive molecular diagnostics for emerging and re-emerging infectious diseases.
• West China Hospital of Sichuan UniversitycoreStrategic or Co-development Partner · 1 January 2023Collaborating institution in the national infectious disease research program under China's 15th Five-Year Plan. Focus on next-generation ultra-fast molecular diagnostics for 19+ high-priority infectious disease targets.
• Grupo T and ITRASIG (Mexico)regionalChannel Partner/ Reseller/ Distributor · 1 January 2023Dr. Octavio Garcia, founder and CEO of Grupo T and ITRASIG, has actively promoted the Nano platform in Mexico through government agency applications and media exposure. Represented at Coyote's 2023 Annual Meeting.
• Tianjin Medical University College of Laboratory MedicineregionalStrategic or Co-development Partner · 1 January 2023Mr. Liu Yunde, Dean of Tianjin Medical University College of Laboratory Medicine, participated in Coyote's 2023 Annual Meeting and 'Preemie Life Rescue Public Welfare Plan' launching ceremony.
• BioSupport (Mexico)regionalChannel Partner/ Reseller/ Distributor · 1 January 2022BioSupport serves as Coyote's partner in Mexico, co-exhibiting at Medical Expo Mexico 2022. Distributes FlashDetect real-time PCR systems including Flash20 and Flash10 in the Mexican market.
• China National Influenza CentercoreStrategic or Co-development Partner · 1 January 2018Coyote undertook National Major Science and Technology Project for Infectious Diseases in 2018, completing validation studies with China's National Influenza Center. Established integrated molecular diagnostic solution for emerging infectious disease response.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 1 January 2015Mini8 portable real-time qPCR analyzer was the first Chinese molecular diagnostic device recruited by WHO for Ebola virus detection. Deployed to Sierra Leone with Chinese medical aid teams during the 2014 West African Ebola outbreak.
• Thermo Scientific (ODM Manufacturer)minorOEM/ Whitelabel/ Licensing Partner · 1 January 2014Coyote became a Thermo Scientific ODM (Original Design Manufacturing) manufacturer in 2014, indicating manufacturing and design capabilities recognized by a major international diagnostics company.
• Peking University, Chinese Academy of Sciences, CUHK, CAMScoreStrategic or Co-development Partner · 1 January 2013Coyote offers postdoctoral positions in collaboration with Peking University, Chinese Academy of Sciences, Chinese University of Hong Kong (CUHK), Chinese Academy of Medical Sciences (CAMS), and other leading institutions. Supports talent development and joint research in molecular diagnostics.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Abbott (ID NOW): Abbott's ID NOW is a rapid molecular POCT instrument widely deployed in urgent care, physician offices, and hospitals for influenza, RSV, and Strep A. Comparable to Coyote's Nano/Flash10 in near-patient use cases, though Abbott is a diversified incumbent offering ID NOW as part of a much broader diagnostics portfolio.
• Roche (cobas Liat): Roche's cobas Liat is a compact, rapid PCR system delivering results in ~20 minutes for SARS-CoV-2, Flu/RSV, Strep A, and CT/NG. Closely comparable to Coyote's FlashDetect in point-of-care workflow and turnaround time; backed by Roche Diagnostics' global commercial scale and broader menu.
• Hologic (Panther Fusion): Hologic's Panther Fusion system provides fully automated, random-access molecular testing for SARS-CoV-2, influenza, RSV, and other respiratory pathogens in hospital and reference lab settings. Comparable in random-access molecular architecture to FlashDetect Flash20/Flash48; Hologic is a much larger women's health and diagnostics incumbent.
• QIAGEN (QIAstat-Dx): QIAstat-Dx is QIAGEN's cartridge-based molecular diagnostic system for syndromic respiratory, gastrointestinal, and meningitis/encephalitis panels. Directly comparable technology architecture to FlashDetect (cartridge + random-access instrument) and similar target customer (hospital labs). QIAGEN is a much larger, publicly-traded life sciences tools incumbent.
• bioMérieux (BioFire): BioFire's FilmArray systems are leading multiplex molecular diagnostic platforms for syndromic infectious disease testing (respiratory, bloodstream, GI, meningitis/encephalitis). Comparable cartridge-based POCT architecture with deeper menu and substantially larger installed base than Coyote; bioMérieux is a globally dominant clinical microbiology incumbent.

Direct peers

• Molbio Diagnostics: Molbio's Truenat system is a chip-based real-time PCR platform for point-of-care infectious disease testing (TB, SARS-CoV-2, HPV, dengue, HIV). Direct technology peer to Coyote in low-cost, portable molecular POCT targeting high-burden infectious diseases in emerging markets, with similar WHO prequalification and global public-sector GTM.
• Sansure Biotech: Sansure Biotech is a leading Chinese molecular diagnostics company offering nucleic acid extraction, PCR reagents, and automated POCT systems (e.g., iPonatic). Direct peer in Chinese infectious disease molecular diagnostics with overlapping menu (SARS-CoV-2, respiratory pathogens, HPV, STIs) and similar GTM into Chinese hospital and CDC channels.
• Mesa Labs (GenMark Diagnostics): GenMark's ePlex system provides sample-to-answer molecular multiplex panels for respiratory, bloodstream, and gastrointestinal infections. Closely comparable to Coyote in offering cartridge-based random-access molecular POCT for infectious disease, targeting hospital and reference lab customers with a similar razor/blade model.
• Cepheid (Danaher): Cepheid's GeneXpert system is the global gold standard in molecular point-of-care PCR testing for infectious diseases (TB, SARS-CoV-2, MRSA, CT/NG). Directly comparable to Coyote's FlashDetect platform in target customers (hospitals, labs, public health) and core cartridge-based molecular POCT business model, though operating at vastly larger scale under Danaher.
• BGI Group (BGI Genomics / MGI Tech): BGI Group operates across the molecular diagnostics value chain, including PCR testing reagents, mobile labs (Huo-Yan/'Fire Eye'), and POCT platforms deployed globally during COVID-19. Closely comparable to Coyote in Chinese-originated molecular POCT for infectious disease, mobile lab deployment model, and international expansion footprint.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/coyote-bioscience

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coyote Bioscience